Hyperlipidaemia gene therapy - AmpliPhi Biosciences

Drug Profile

Hyperlipidaemia gene therapy - AmpliPhi Biosciences

Alternative Names: AAV-VLDLR

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Targeted Genetics Corporation
  • Developer AmpliPhi Biosciences Corporation; Targeted Genetics Corporation
  • Class Antihyperlipidaemics; Gene therapies
  • Mechanism of Action LDL receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • Available For Licensing Yes - Hyperlipidaemia

Highest Development Phases

  • No development reported Hyperlipidaemia
  • Discontinued Hyperlipoproteinaemia type II

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Hyperlipidaemia in USA
  • 09 Mar 2011 Targeted Genetics Corporation is now called AmpliPhi Biosciences
  • 11 Nov 2010 This programme is in active development
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top